Several case reports demonstrated that the administration of systemic tissue plasminogen activator (tPA) was associated with improvement in the respiratory status of patients affected by severe COVID-19 [87], although the risk of severe bleeding represents a serious concern. This evidence concerns the gene PLAT and COVID-19.